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g.2013.0Abstract The aim of the present study is to evaluate, for the ﬁrst time, antigenotoxic potential of
Agaricus bisporus against methyl methanesulphonate induced toxicity in human lymphocyte culture
in vitro and in bone marrow cells of albino mice in vivo. The parameters studied included total aber-
rant cells and the frequencies of aberrations in the bone marrow cells at three exposure durations
viz., 16, 24 and 32 h, and for the in vitro method using chromosomal aberrations, sister chromatid
exchanges and replication indices as markers. The alcoholic extract of A. bisporus was taken in ﬁve
increasing concentrations of 200, 250, 300, 350 and 400 mg/kg body weight for three in vivo expo-
sure durations viz., 16, 24 and 32 h. Similarly, four doses of extracts viz., 150, 200, 250 and 300 lg/
ml of culture were taken for in vitro durations of 24, 48 and 72 h in the presence as well as the
absence of S9-mix. The treatment reduced the total number of aberrant cells ranging from 10.0%
to 46.15% and it reduced the total frequencies of aberrations ranging from 198 to 96 against very
high aberrations i.e., 227 caused due to methyl methanesulphonate in vivo. The same trends were
observed in the in vitro experiments i.e., it reduced chromosomal aberrations from (42.00%,
71.25%, and 83.00% to 20.00%, 39.50%, and 43.00%) at 24, 48, and 72 h of exposure respectively.ation, SCE, sister chromatid
, methyl methanesulphonate,
M.S. Ahmad).
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396 M.S. Ahmad et al.However when experiments were carried out in the presence of liver S9 fraction, these values were
respectively 52.38, 44.56, and 48.34% signiﬁcant at <0.05 level, likewise it also reduced sister chro-
matid exchanges from 14.86 ± 1.44 down to 8.84 ± 0.75 per cell, whereas the replication index got
enhanced from 1.45 to 1.64.
 2013 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Dietary mushrooms have been used globally since millennia to
promote health and prevent and treat various diseases due to
their multitude of medicinal qualities [1]. The number of differ-
ent mushroom species on earth is estimated at 140,000 of
which only 10% is known [2]. In general, medicinal dietary
mushrooms have been shown to improve cardiovascular
health, stimulate immune function and contribute to glucose
homeostasis and to modulate detoxiﬁcation, as well as exert
anti-allergic, antiviral, antibacterial, antifungal and anti-
inﬂammatory activities [3].
The use of mushrooms with potential therapeutic properties
has greatly raised global interest in the scientiﬁc as well as clin-
ical community based on twomain reasons. Firstly, mushrooms
demonstrate their efﬁciency against numerous diseases includ-
ingmetabolic disturbances as serious as cancer and degenerative
diseases. Secondly, these therapeutic effects seem to encompass
multiple complex pharmacological actions on different cellular
and molecular targets [4]. The most signiﬁcant medicinal effects
of mushrooms and their metabolites that have attracted the
attention of the public are their antitumor properties [5,6].
Themedicinal use of ediblemushroomextracts seems to bemore
of a natural and less expensive approach and, in general, in-
volvesminimal unwanted side effects.Moreover, puriﬁed bioac-
tive compounds derived from edible mushrooms might be
potentially important new sources of anticancer agents. It has
been known for many years that selected mushrooms of higher
basidiomycetes origin are effective against certain types of can-
cer which have stirred a great interest in the use of such mush-
rooms across industry, media and the scientiﬁc community [2].
In recent years, multiple drug resistance in human patho-
genic microorganisms has been reported to indiscriminate the
use of commercially used antimicrobial drugs for the treatment
of infectious diseases. Extracts from fruiting bodies and the
mycelia of variousmushrooms have been reported to cause anti-
microbial activity against a wide range of infectious bacteria [7].
2. Materials and methods
The whole plant of A. bisporus was dried in the shade at room
temperature. The shade dried plants were powdered and 60 g
of coarse powder was defatted with petroleum ether and ex-
tracted exhaustively with 95% methanol at a temperature of
60 C. The extract was dried by a vacuum evaporator. Metha-
nolic extract of A. bisporus was dissolved in dimethyl sulphox-
ide (DMSO) to prepare different optimum concentrations for
studies following earlier methodology [8].
2.1. In vivo method
Albino mice 8–10 weeks old (25–35 gm in weight) were ex-
posed to different test chemicals by appropriate routes (intraperitoneal i.e., I.P injection) and were sacriﬁced at sequential
intervals of 16, 24, and 32 h of stipulated treatment time. Ani-
mals were treated with each test substance as shown in the ta-
bles (Table A). Further processes of slide preparations, cells
and chromosomal aberrations analyses are adopted from ear-
lier published work [8].
The reduction factors due to test chemical treatments were
calculated using the formula:
%Reduction¼ðAberrant cells inMMS controlaberrant cells inMMSwithAgaricusextractsÞðAberrant cells inMMS controlaberrant cells in negative controlÞ2.2. In vitro lymphocytes culture method
Human peripheral blood lymphocytes are extremely sensitive
indicators of the in vitro assay system. The chromosomal
changes (numerical and structural) were utilized for investiga-
tion of the genotoxic as well as antigenotoxic potentiality of
test chemicals. The parameters studied included chromosomal
aberrations (CA), sister chromatid exchanges (SCEs) and cell
growth kinetics (RI) both in the presence and in the absence
of the exogenous metabolic activation system. The in vitro cul-
ture methods, preparation of S9 (microsomal fraction), media
preparation and analyses of chromosomal aberrations, sister
chromatid exchanges, cell cycle kinetics and statistical analysis
were followed as per earlier methodology.[8]
The replication index (RI) was calculated according to the
formula of Tice et al. [9] as given below. The deviation from
the controls was determined by using the Chi-square (v2) test.
R:I ¼ ðM1X1Þ þ ðM2X2Þ þ ðM3X3Þ
1003. Results
3.1. In vivo effects
The results following the treatment of A. bisporus extract with
methyl methanesulphonate (MMS) were tabulated at three dif-
ferent durations of 16, 24 and 32 h. The results show that the va-
lue after treatment withMMS only at 16 h was 12.0%, while the
same treatment with ﬁve different increasing concentrations of
A. bisporus with MMS, reduced the values down to 11.9%,
10.8%, 9.1%, 8.9% and 8.5% respectively, the same values for
normal and DMSO controls respectively were 2.1% and 2.0%.
In terms of percent reduction in the number of aberrant cells,
the observed values respectively were 08.3%, 10.0%, 24.16%,
25.83% and 29.16% for ﬁve different doses of A. bisporus ex-
tract. The results showed thatA. bisporus extract at each concen-
tration reduced the total aberrant cells signiﬁcantly (Fig. 1).
The total numbers of frequency in the aberrant cells were
198 for MMS alone, whereas the same were 206, 169, 146,
138 and 124 in numbers for ﬁve different doses of A. bisporus
extract respectively. The reduced values are statistically
Figure 1 Shows in vivo anticarcinogenic effect of Agaricus
bisporus extracts at 16, 24, and 31 h of treatment durations against
MMS genotoxicity in albino mice bone marrow cell (signiﬁcant at
P< 0.05 level).
Table A In vivo concentrations of phyto-chemicals.
Phyto-products 1st dose 2nd dose 3rd dose 4th dose 5th dose
Alcoholic extracts of Agaricus bisporus in vivo (mg/kg bw) AB1 200 AB2 250 AB3 300 AB4 350 AB5 400
Alcoholic extracts of Agaricus bisporus in vitro(lg/ml) AB1 150 AB2 200 AB3 250 AB4 300 Nil
Positive and Negative Controls (lg/ml) (+) MMS 5 (-)DMSO 5 Nil Nil Nil
Note: In the in vivo experiments ﬁve increasing doses were used whereas for in vitro experiments only four doses were tested, Methyl metha-
nesulphonate and Dimethyl sulphoxide were used as positive and negative controls respectively.
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bisporus extract increases, the total frequency decreases, thus
it shows a dose-dependent relationship. Cells with ﬁve or more
aberrations were very few in numbers. A similar trend was ob-
tained after 24 h of treatments. The obtained value of percent
aberrant cells was 13.0% for MMS and 11.0%, 9.0%, 8.0%,
7.9% and 7.0% for ﬁve different concentrations of A. bisporus
extract along with MMS. The percent reductions in the aber-
rant cells were 15.38%, 30.76%, 38.46%, 39.23% and
46.15% which shows very signiﬁcant effect of different concen-
trations of the extract. It showed a dose dependent relationship
between the doses of the extract and percentage reduction of
the aberrant cells (Table 1 Fig. 1). The frequency of aberrant
cells was recorded (Table 2). The values recorded were 222
aberrations for MMS and 145, 132, 107, 110 and 96 aberra-
tions for the extracts plus MMS. The trends of reductions were
dose dependent for the extracts (Table 2).
After 32 h of experiments the value obtained for the total
number of aberrant cells was 151 for MMS alone while this
number gets reduced to 140, 130, 110, 94 and 86 for their
respective increasing concentrations of A. bisporus extract gi-
ven with MMS. In terms of percent reductions in the number
of aberrant cells, the extract showed a very much effective ac-
tion in reducing the aberrant cells. The values for ﬁve concen-
trations of A. bisporus extract were 07.28%, 13.90%, 27.54%,
37.08% and 43.00% as shown in Fig. 1. The total frequency ofaberrations followed a similar trend. The values recorded were
227 aberrations for MMS and 198, 171, 145, 119 and 119 aber-
rations for the extracts plus MMS.
3.2. In vitro effects
All the cultures were treated with Methyl methanesulphonate
(MMS) at three different durations viz., 24, 48 and 72 h. The
results of the treatment obtained in terms of clastogenic abnor-
malities in percent metaphase aberration, types of aberrations
and aberrations per cell respectively are as follows viz.,
40.00%, 58.50%, 69.75% and 0.40%, 059%, 0.70% aberra-
tions calculated per cell respectively, while the control values
for normal and DMSO plus A. bisporus extracts are 3.50,
4.75 percent at single standard doses at three different dura-
tions viz., 24, 48 and 72 h. The A. bisporus extract brings down
aberrations from 40.00% to 32.00%, 27.75%, 23.25% and
21.00% with four consecutive doses at 24 h of duration,
whereas at 48 h, it got lowered from 58.50% to 52.00%,
45.25%, 41.75% and 37.25% respectively by Ist to 4th concen-
trations of A. bisporus extracts. The same trend was noticed,
when the treatment durations were increased to 72 h. These
values show linear increasing trends with duration and doses
of extracts. The maximum percentage reductions in the aberra-
tions were 47.50% for 24 h and 36.32% and 42.65% for 48 and
72 h respectively, obtained due to the highest doses of A. bisp-
orus extracts (Fig. 2).
Similarly when the experiment was setup along with the
metabolic activation system (+S9 mix), the effect of MMS
got increased. The effect of the A. bisporus extract also showed
similar increasing antigenotoxic trends as they lowered the
clastogenic activity of MMS. The values showed linear in-
crease with dosages (Table 3 and Fig. 3). The maximum effec-
tive percentage reductions were 52.38%, 44.56% and 48.35%
for 24, 48 and 72 h respectively. The highest reduction for clas-
togeny of cells was noticed at 24 h durations; though the other
values were also statistically signiﬁcant at P< 0.05 level.
The data obtained from the experimental setup for sister
chromatid exchanges are indicated in Table 4 and show a
reduction in SCE in the absence as well as in the presence of
the metabolic activation system; there was a lowering of the
mean range and of the total SCEs and SCE per cell from
13.30 to 07.60 and from 14.86 to 8.84. For the analysis of
SCE, only 48 h cultures were used and only 50 metaphases
were scanned (Fig. 4).
The effects of A. bisporus extract on the replication index
are shown in Table 5 and seem to elevate the level of the index
when compared to the MMS treatment alone i.e. from 1.46 to
1.67; (though still lower than the normal level of 1.76). After
being treated with the metabolic activation system, it was en-
hanced from 1.40 to 1.61. The A. bisporus extract, therefore,
Table 1 Effect of Agaricus bisporus on the frequency of cells with chromosome aberrations induced by methyl methanesulphonate
(MMS x/kg.bw) at 24 h duration.
Treatment Agaricus bisporus
extract (Y/kg.bw)
Cells with pulverized
chromosome
Types of chromatid aberrations Aberrant cells (%) Reduction
Gaps Breaks Fragments Exchanges Number Percentage
DH2O 0 00 03 04 16 00 20 2.0
DMSO 0 00 02 02 17 00 19 1.9
MMS+DMSO 13 98 40 73 02 130 13.0
AB AB5 00 04 05 15 00 20 2.0
MMS+ AB AB1 09 35 36 65 00 110 11.0 15.38
AB2 05 55 32 51 01 90 9.0 30.76*
AB3 04 27 30 46 00 80 8.0 38.46*
AB4 04 31 28 47 00 79 7.9 39.23*
AB5 00 26 26 44 00 70 7.0 46.15*
Note: AB; concentrations of alcoholic extracts of Agaricus bisporus,MMS x/kg.bw; 5 lg/ml /kg body weight) at 24 h of treatment. Calculations
were made excluding the gaps type of aberration and *signiﬁcant at <0.05 probability. Y/kg.bw is the concentration of alcoholic extracts of
Agaricus bisporus.
Figure 2 Comparative in vitro anticlastogenic effect of Agaricus
bisporus extracts in the absence of S9 mixture at 24, 48 and 72 h of
treatment duration (signiﬁcant at P< 0.05 level).
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experiments.
4. Discussion
The role of phenolic compounds in acting as scavengers of free
radicals is widely reported [10]; phenolic compounds play a
major role in antioxidant activities shown by many vegetables
[11]. It is suggested that polyphenolic compounds have inhibi-
tory effects on mutagenesis and carcinogenesis in humans,
when ingested daily from a diet rich in fruits and vegetables
[12]. In a study, performed with A. bisporus, it was thought
that the high free radical-scavenging activity and total antiox-
idant activity may result from the existence of the phenolics
and the ﬂavonoids.
The activity of ingredients against HL60 cells shows anti-
proliferative property, though there have been a number of re-
ports which show that basidiomycetes have antitumor activity
including antioxidant defense for the host immune system po-
tential [13]. Many reports indicate that most of the polysaccha-
rides or polysaccharide protein complexes from mushroom
and natural sources cause direct cytotoxic effects on tumorTable 2 Effect of Agaricus bisporus (AB) extract on the frequency of cells with chromosome aberrations induced by methyl
methanesulphonate (MMS x/kg.bw) at 24 h duration.
Treatment Agaricus bisporus extract (Y/kg.bw) Cells with aberrations Total number of aberrations
0 1 2 3 4 5 6–9
DH2O 0 980 17 03 00 00 00 00 23
DH2O+ DMSO 0 981 17 02 00 00 00 00 21
MMS 0 870 73 20 16 06 04 01 222
AB AB5 980 16 04 00 00 00 00 24
MMS+ AB AB1 890 81 15 07 02 01 00 145
*
AB2 910 62 12 08 02 01 01 132
*
AB3 920 60 10 02 04 01 00 107
*
AB4 921 52 10 05 03 02 00 110
*
AB5 930 57 06 02 04 01 00 96
*
Note: AB; concentrations of alcoholic extracts of Agaricus bisporus,MMS x/kg.bw; 5 lg/ml /kg body weight) at 24 h of treatment. Calculations
were made excluding the gaps type of aberration and *signiﬁcant at <0.05 probability. Y/kg.bw is the concentration of alcoholic extracts of
Agaricus bisporus. The animals were sacriﬁced 24 h after MMS treatment 1000 cells from 10 animals were analyzed for each point. Y/kg.bw is
the concentration of alcoholic extracts of Agaricus bisporus.
Table 3 Analysis of chromosomal aberration after treatment with Methyl methanesulphonate (MMS) along with Agaricus bisporus
(AB) extract in vitro, in the presence of S9 mix.
Treatments Durations (h) Metaphase scored Percent aberration metaphase Types of Aberration (%) AberrationCell  SE
Including gaps Excluding gaps Chromatid Chromosome Total
MMS 24 200 40.50 38.25 31.50 10.50 42.00 0.42 ± 0.03
48 200 42.75 41.50 47.00 24.25 71.25 0.71 ± 0.05
72 200 52.00 46.50 54.25 29.00 83.25 0.83 ± 0.07
MMS+ AB1 24 200 25.75 21.00 23.00 11.00 34.00 0.34 ± 0.02
48 200 34.00 29.75 40.50 20.50 61.00 0.61 ± 0.04
72 200 29.00 28.75 42.75 24.00 65.75 0.66 ± 0.06
MMS+ AB2 24 200 26.75 21.00 18.25 10.00 28.25 0.28 ± 0.03
48 200 34.75 29.25 38.25 17.25 55.50 0.56 ± 0.04
72 200 32.25 28.75 36.75 20.75 57.50 0.58 ± 0.06
MMS+ AB3 24 200 22.75 19.50 12.00 09.75 21.75 0.22 ± 0.03
48 200 32.75 28.50 31.25 12.50 43.75 0.44 ± 0.05
72 200 25.00 22.25 32.00 16.75 48.75 0.49 ± 0.04
MMS+AB4 24 200 19.75 16.75 12.50 07.50 20.00 0.20 ± 0.03
48 200 30.00 27.75 28.00 11.50 39.50 0.40 ± 0.04
72 200 38.25 33.50 30.00 13.00 43.00 0.43 ± 0.06
CONTROL
Normal 72 200 4.00 3.25 2.00 1.25 3.25 4.50 ± 0.01
DMSO+AB2 72 200 5.75 4.25 2.75 1.50 4.75 6.25 ± 0.01
Note: AB; concentrations of alcoholic extracts of Agaricus bisporus MMS x/kg.bw; Methyl methanesulphonate 5 lg/ml/culture, gaps type of
aberration is not included, SE; Standard error, Calculations were signiﬁcant at <0.05 probability level.
Figure 3 In vitro anticlastogenic effect of Agaricus bisporus
extracts in the presence of S9 mixture at 24, 48 and 72 h of
treatment duration (signiﬁcant at P< 0.05 level).
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type of inhibitory action may be interwoven and the mecha-
nism of action may vary from person to person as also the type
of cancer [14]. Ergosterol, a phenolic compound extracted
from the white button mushroom, shows the inhibitory effect
on breast cancer cell line in vitro by aromatase inhibition with-
out side effects [15].
A frequently reported protective mechanism exerted by
mushrooms against cancer is the capacity to stimulate the im-
mune system response where b-glucan, a water-soluble poly-
saccharide, is presumed to activate certain immune cellsand the proteins that attack cancer, including macrophages,
T-cells, natural killer cells, and interleukin-1 and interleu-
kin-2 [2,16]. Dietary mushrooms such as A. bisporus have
also been shown to alter aromatase activity, an enzyme that
is involved in the conversion of androgens to proliferative
estrogenic intermediates, which are closely linked to breast
cancer development [17]. Mushroom extracts contain other
components such as lentinan and lectins, which are directly
cytotoxic and cytostatic to tumor cells such as MCF-7 breast
cancer cells [18]) A. bisporus also contains bioactive antioxi-
dants and anticarcinogenic substances including ergothione-
ine, selenium and polyphenols. Furthermore, studies have
indicated that non-polysaccharide constituents in mushrooms
have biological activity against murine skin cancer and hu-
man prostate carcinoma cells [19]. Collectively, there are
many bioactive agents in mushrooms that can exert beneﬁcial
effects acting co-operatively in systems with different cell
types, i.e. immunity, or exhibit cytotoxicity directly on the
cancer cells.
Many diverse species of mushrooms and their respective
bioactive agents have also demonstrated the capacity to inhibit
cellular proliferation of human breast cancer cells in vitro. Iso-
lated lectins from Pholiata adipose and Inocybe umbrinella ex-
ert strong antiproliferative activity toward MCF-7 and HepG2
human hepatoma cells with IC50 in the range of 1.9–7.5 lmol/
L [20,21]). An isolated A. bisporus, or WB, lectin inhibits the
incorporation of 3H-thymidine into DNA by as much as
50% in MCF-7 cells and by 87% in HT29 colon cancer cells,
about 16% in Caco-2 colon cancer cells, and by 55% in rat
mammary ﬁbroblasts (after 24 h incubation). This is in agree-
ment with our observations since we have noted 33% reduc-
tion in BrdU incorporation after 24 h of incubation using
in vitro human lymphocyte cultures. Numerous species of
mushrooms when delivered as whole mushroom extracts or
their isolated bioactive components, and their metabolites,
Table 4 Analysis of sister chromatid exchanges (SCE) after treatment with Methyl methanesulphonate along with Agaricus bisporus
(AB) extract in vitro, in the presence of S9 mix.
Treatment Duration (Hrs.) Metabolic activation Metaphase scanned Total SCE Range SCE/Cell ± SE
Aﬂatoxin B1 48 +S9 50 743 3–12 14.86 ± 1.44
AFB1 + AB1 48 +S9 50 646 2–11 12.92 ± 1.14
AFB1 + AB2 48 +S9 50 570 1–10 11.40 ± 1.00
AFB1 + AB3 48 +S9 50 522 1–9 10.44 ± 0.90
AFB1 + AB4 48 +S9 50 442 0–7 8.84 ± 0.75
Normal 48 +S9 50 115 0–4 2.30 ± 0.40
DMSO 48 +S9 50 108 0–5 2.16 ± 0.40
DMSO+ AB2 48 +S9 50 103 0–5 2.06 ± 0.40
Note: AB; concentrations of alcoholic extracts of Agaricus bisporus, MMS x/kg.bw; methyl methanesulphonate 5 lg/ml/ culture, DMSO;
dimethyl sulphoxide, SCE; Sister chromatid exchange, SE; Standard error, Calculations were made at <0.05 probability level.
Figure 4 Antigenotoxic effect of Agaricus bisporus extracts on
sister chromatid exchanges in the absence as well as in the presence
of a metabolic activation system. Total 50 metaphase plates were
scored at 48 h of treatment durations (signiﬁcant at P< 0.05
level).
400 M.S. Ahmad et al.can inhibit cellular proliferation, suggesting that this is a key
mechanism of action.Table 5 Analysis of cell cycle kinetics after treatment with methy
in vitro, in the presence of S9 mix.
Treatment Cell scored Percent aberration metaphase
M1 M2
MMS 200 55 40
MMS+ AB1 200 53 42
MMS+ AB2 200 49 44
MMS+ AB3 200 45 45
MMS+ AB4 200 45 43
Normal 200 41 46
DMSO 200 33 50
DMSO+ AB2 200 33 49
Note: 2 · 3 Chi square (v2) test was conducted, AB; concentrations o
methanesulphonate 5 lg/ml/ culture. Calculations were made at <0.05 pThere have been many mechanisms proposed for the inhib-
itory action of mushrooms including that of the immune sys-
tem and boosting the cell signaling inhibition. For example,
studies show that shiitake has tumor-inhibitory effects on pro-
liferation possibly through reduction in natural killer cell cyto-
toxicity in rodent studies [22]. In a study, it was conﬁrmed that
OYS mushroom extracts potently inhibit proliferation by
inducing cell cycle arrest at the G0/G1 phase in MCF-7 cells
[6]. Alternately, an extract of A. blazei inhibits cell growth in
a dose-dependent manner through the arrest of cells in the
G2/M phase and induction of apoptosis [23]. This is consistent
with our results where proliferation was not altered as indi-
cated by the replication index (RI) cell counts, though DNA
replication clearly was decreased, suggesting an effect on the
cell cycle. During the G1 to S transition, cells are recruited
for cellular proliferation through DNA replication, however
if cells are arrested at this checkpoint, viz. G0/S, then DNA
replication will get reduced or even prevented. Our results thus
indicate a 30% reduction by the test of mushrooms on muta-
genesis, as measured by BrdU incorporation, indicative of a
block in DNA replication.
It was demonstrated that Pleurotus ostreatus induces G0/G1
cell cycle arrest of MCF-7 cells by the up-regulation of the
expression of p53 and p21, whereas cell cycle arrest of HT-
29 is induced at G0/G1 by the up-regulation of the expression
of p21 [24]. Deregulated cell cycle progression is a common
abnormality observed in human cancers. Progression through
the cell-division cycle is regulated by the coordinated activitiesl methanesulphonate along with Agaricus bisporus (AB) extract
Replication Index 2 · 3 Chi square (v2) test
M3
05 1.46
05 1.52 **Signiﬁcant
07 1.58 *Signiﬁcant
10 1.65 *Signiﬁcant
12 1.67 *Signiﬁcant
13 1.72
17 1.84
18 1.85
f alcoholic extracts of Agaricus bisporus, MMS x/kg.bw; Methyl
robability level.
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vel of regulation of these cyclin-CDK complexes is provided
by their binding to CDK inhibitors (CKIs) [25]. In a study it
was observed, using cDNA microarray technology and Wes-
tern blot analysis, P. ostreatus up-regulated the expression of
p21 and p53 in MCF-7 cells which had wild-type p53 [26].
Thus, treatment of MCF-7 cells by P. ostreatus may lead to
the induction of p21 by p53 dependent mechanisms in MCF-
7 cells. The increase of p53 protein levels in MCF-7 cells trea-
ted with P. ostreatus suggests that its inhibitory properties for
growth may involve the induction of DNA damage response.
The C terminus of p21, containing its nuclear localization sig-
nal, binds to or inhibits PCNA, thereby blocking DNA repli-
cation [27]. In the study, it was demonstrated that P.
ostreatus slightly decreased the protein level of PCNA in
MCF-7 treated cells, which may also contribute to the de-
creased DNA synthesis. However, expression of PCNA in
HT-29 treated cells was not affected by P. ostreatus [26].
5. Conclusion
Alcoholic extracts of A. bisporus reduce the total aberrant cells
ranging from 10.0% to 46.15% and it reduces the total fre-
quencies of aberration from 198 to 96 against 227 aberrations
caused due to MMS alone in vivo. The same trends were ob-
served in the in vitro experiments i.e., it reduces chromosomal
aberrations to 47.50% for 24 h and 36.32% and 42.65% for 48
and 72 h respectively; however when experiments were carried
out in the presence of the liver S9 fraction, these values are
52.38%, 44.56% and 48.35% respectively, being signiﬁcant
at <0.05 level, likewise it also reduces sister chromatid ex-
change from 14.86 to 8.84 per cell and enhances the replication
index from 1.45 to 1.64.
Alcoholic extracts of A. bisporus signiﬁcantly reduce the
number of aberrant cells and the frequency of aberrations
per cell at each concentration and duration of exposure
in vivo; similarly it reduces chromosomal aberrations and sister
chromatid exchange but enhances the replication index in vitro,
both of which are statistically signiﬁcant at <0.05 level.
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